These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24428199)

  • 21. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
    Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
    JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.
    Shah HJ; Keraliya AR; Jagannathan JP; Tirumani SH; Lele VR; DiPiro PJ
    Korean J Radiol; 2017; 18(1):54-70. PubMed ID: 28096718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of follow-up endoscopic examination in treatment response assessment for patients with gastric diffuse large B cell lymphoma.
    Yoon SB; Lee IS; Lee HN; Kim E; Kim W; Lee HH; Lee BI; Choi MG; Jung SE; Choi BO; Park GS; Cho SG
    Scand J Gastroenterol; 2016 Sep; 51(9):1111-7. PubMed ID: 27175513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphopenia predicts preclinical relapse in the routine follow-up of patients with diffuse large B-cell lymphoma.
    Wei X; Wei Y; Huang F; Jing H; Xie M; Hao X; Feng R
    Leuk Lymphoma; 2015 May; 56(5):1261-5. PubMed ID: 25175043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
    Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
    Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.
    Lehners N; Krämer I; Schwarzbich MA; Ho AD; Witzens-Harig M
    Leuk Lymphoma; 2016 Nov; 57(11):2619-25. PubMed ID: 26999040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission.
    Truong Q; Shah N; Knestrick M; Curley B; Hu Y; Craig M; Hamadani M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):50-5. PubMed ID: 24119465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.
    Picardi M; Pugliese N; Cirillo M; Zeppa P; Cozzolino I; Ciancia G; Pettinato G; Salvatore C; Quintarelli C; Pane F
    Radiology; 2014 Jul; 272(1):262-74. PubMed ID: 24708193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
    Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
    Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
    Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
    Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
    Modvig L; Vase M; d'Amore F
    Br J Haematol; 2017 Oct; 179(1):75-82. PubMed ID: 28653321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.